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OBJECTIVE: We sought to examine the presence and severity of brain small 
vessel disease in a group of patients with type 2 diabetes (T2D) and diabetic 
retinopathy (DR) compared with a group of patients with T2D without DR.  
METHODS: A total of 312 patients with T2D (men, 51%; mean age, 57 yrs; age 
range 40–75 yrs) were included in the study; 153 (49%) of the patients had DR. 
A brain magnetic resonance was perfomed to evaluate the presence and 
severity (ARWMC scale) of white matter lesions and microbleeds. A transcranial 
Doppler ultrasonound was performed to measure the Gosling’s pulsatility index 
of the middle cerebral artery (MCA-PI).  
RESULTS: No differences were observed in the prevalence of LA between 
patients with or without DR (39.72% vs 30.76%, p=0.0638). The severity of LA 
was significantly higher in patients with DR compared to those without DR 
(p=0.0429). In the regression analysis age (p<0.001) and systolic blood 
pressure (p=0.0244) were associated with LA. No differences were observed in 
the presence of microbleeds between patients with or without DR (2.5% vs 
3.5%, p=0.45). Patients with DR showed a higher MCA-PI compared to those 
without DR (p<0.0001). Variables associated with an increased MCA-PI in the 
regression analysis were age (p<0.0001 ),systolic and dyastolic blood pressure 
(p=0.0001) and retinopathy (p=0.037). A positive correlation was found between 
severity of LA and MCA-PI values (p=0.0058).   
CONCLUSIONS: Patients with T2D and DR have a more severe grade of LA 
and higher MCA-PI values compared to those without DR. Moreover, in these 
patients MCA-PI and LA severity are positively associated. Our findings support 
the hypothesis that the brain is a target organ for microangiopathy similar to 
other classic target organs such the retina.  
 
  
Introduction 
Patients with type 2 diabetes mellitus (T2D) have an increased risk for 
cardiovascular morbidity and mortality. The chronic deleterious effects of 
hyperglycaemia are classically separated into microvascular and macrovascular 
complications. The main clinical entities of diabetic microvascular disease 
include retinopathy, neuropathy, and nephropathy, while stroke, acute coronary 
syndromes and peripheral vascular disease are classified as macrovascular 
complications of T2D (1).  Despite intensified blood glucose control, patients 
with T2D remain at greatly increased risk for macrovascular events such as 
ischemic stroke (2).  In these patients a high prevalence atherotrombotic 
disease has been described in large extracranial vessels such as internal 
carotid artery (3). Furthermore, besides classical target organs of 
microangiopathy such as the retina or the kidneys, the brain has also been 
described more recently as a target organ for diabetic microvascular 
complications (4). Cerebral small vessel disease (SVD) is the term commonly 
used to describe a syndrome of clinical, cognitive, neuroimaging, and 
neuropathological findings thought to arise from disease affecting the 
perforating cerebral arterioles, capillaries, and venules, and the resulting brain 
damage in the cerebral white and deep grey matter (5). At MRI examination 
SVD, as outlined in the Standards for Reporting Vascular Changes on 
Neuroimaging (STRIVE) position paper, can show distinct forms:  most typically, 
symptomatic small subcortical infarcts, subclinical lacunes, white matter 
hyperintensities, and cerebral microbleeds (6). Leukoaraiosis (LA) or white 
matter disease is a descriptive term to denominate cerebral white matter lesions 
(WMLs) frequently seen on brain imaging which is considered to be a 
radiological sign of tissue damage produced by chronic ischemia caused by 
SVD (7). Different terms such as white matter (WM) hyperintensities, WM 
changes, WM disease and WM lesions are used as synonyms of LA (8).  It is 
associated with cognitive decline and a higher risk of stroke and death. 
Moreover, its severity and progression indicates an increased risk of 
cerebrovascular events (9,10). Studies of the relationship between diabetes and 
WM disease have shown conflicting results. Several studies have reported an 
association between diabetes and LA, while others have not confirmed this 
association (11,12).  
Microbleeds are small (generally 2–5 mm in diameter, but sometimes up to 10 mm) 
areas of signal void with associated blooming seen on T2*-weighted MRI or other 
sequences that are sensitive to susceptibility effects (13).  Histo- pathological studies 
indicate that these lesions reflect haemosiderin-laden macrophages in 
perivascular tissue consistent with vascular leakage of blood cells at capillary, 
small artery and arteriolar levels (14).  
Finally, another method used for the evaluation of cerebral SVD is the 
measurement of vascular resistance by using a pulsatility index (PI) by 
Transcranial Doppler ultrasonography( TCD) which has long been proposed to 
reflect vascular resistance of the small vessels. Several studies have 
demonstrated increased PI in patients with WM disease (15,16), including 
populations of hypertensive patients (17) and patients with diabetes mellitus 
(18). 
The microvascular bed of the retina mirrors the cerebral small vessels in 
embryological origin, anatomic features, and physiologic properties (19). Cross-
sectional studies performed in general population show that people with 
retinopathy are more likely to have concomitant cerebral infarct, WMLs and 
microbleeds on MRI than those without retinopathy (20,21). Moreover, 
prospective studies also perfomed in general population show evidence that the 
presence of microvascular retinal abnormalities are associated with incident 
stroke and subclinical infarcts (22,23). More recently, presence of any 
retinopathy has also been reported to be associated with a greater progression 
of LA (24).  
In patients with diabetes it has been reported that the presence and severity of 
retinopathy are associated with future CV events including ischemic stroke        
(25-27). 
In the present study we sought to examine whether there was any difference in 
the presence and severity of several markers of cerebral SVS (LA, microbleeds 
and PI index) in a group of patients with T2D and retinopathy compared with a 
group of patients with T2D without retinopathy, both of them without previous 
CV events.  
Research Design and Methods 
Subjects 
The study design and assessments of the cohort participants have been 
previously described by our group in a previous study in the presence and 
extension of carotid plaques was analyzed in patients with T2D with and without 
DR (28). Briefly, 312 subjects with T2D without previous cardiovascular events 
and with a normal renal function were recruited from the outpatient clinic at our 
centre. One-hundred fifty-three patients with DR and 159 without DR were 
included in the study. An experienced ophthalmologist assessed and classified 
retinopathy according to an international consensus on clinical diabetic 
retinopathy (29) as follows: a) mild nonproliferative DR - microaneurysms only; 
b) moderate nonproliferative DR - more than just microaneurysms but less than 
severe nonproliferative DR; c) severe nonproliferative DR by any of the 
following - more than 20 intraretinal haemorrhages in each of 4 quadrants, 
definite venous beading in 2+ quadrants, prominent intraretinal microvascular 
abnormalities in 1+ quadrant, and no signs of proliferative retinopathy; and d) 
proliferative DR, by neovascularization and/or vitreous/preretinal haemorrhage. 
The sex distribution did not differ between groups. However, as expected, age, 
cardiovascular risk factors, disease duration, and microalbuminuria were 
different between groups due to the selection criteria or the metabolic condition 
or disease stage of the participants. Diabetic patients with retinopathy, 
compared with those without retinopathy, had higher prevalence of 
hypertension, systolic blood pressure, waist circumference, HbA1c 
concentration and urinary albumin excretion, and were more frequently treated 
with insulin (alone or in combination with oral agents) and aspirin.  
Methods 
In the present study, a brain MR was performed in 289 patients because of 
contraindication for MRI study in 15 patients (claustrophobia in 13) and lack of 
complicance with the appointed visit in 8 cases. We calculated mean MCA PI by 
averaging bilateral MCA PI. Mean MCA PI of good quality was obtained in 218 
patients (115 patients with retinopathy and 103 patients without retinopathy).  
The local Ethics Committee approved the protocol, and all patients signed the 
written informed consent form. 
MRI study protocol. Brain MR images were acquired on a Philips Intera 1.5 T, 
The Netherlands, with a standardised protocol. The protocol comprised an axial 
T2-weighted turbo spin-echo (4800/120/3; TR/TE/excitations), T1-weighted 
spin-echo (540/15/2), turbo fluid-attenuated inversion recovery 
(8000/2200/120/2; TR/TI/TE), and echo-planar diffusion images (3900/95).  
White matter lesions (WMLs) were scored according to age-related white matter 
changes (ARWMC) scale (30). It is a simple and well-validated scale applicable 
to both CT and MRI with a good interrater reliability. The degree of white matter 
changes is rated on a 4-point scale from 0 to 3 in five different regions (frontal, 
parieto-occipital, temporal, basal ganglia, infratentorial) in the right and left sides 
of the brain separately, on T2 and FLAIR images. The rating scores were: 0: No 
lesions (including symmetrical, well-defined caps or bands), 1:  Focal lesions, 2: 
Beginning confluence of lesions, 3: Diffuse involvement of the entire region, with 
or without involvement of U fibers. To analyze the correlation between LA 
severity and retinopathy patients were categorized into two groups taking into 
account the results obtained in the ARWC score (group A: absence of or mild 
LA, and group B moderate and severe LA). 
We used the microbleed anatomical rating scale (MARS) to measure the 
number and distribution of microbleeds in the brain (31). This reliable scale 
classifies microbleeds into definite and possible categories. The initial study 
protocol included defined patients with microbleeds as those with definite 
lesions. The number of microbleeds is rated in different infratentorial, deep and 
individual lobar regions in the right and left sides, similar to ARWMC scale. This 
allows to study the distribution of microbleeds and to correlate it with the 
distribution of white matter changes.  
WMLs and microbleeds were scored by a single trained neuroradiologyst (JD) 
who was blinded to the patient’s clinical data. 
Transcranial Doppler ultrasonography.  
All TCD studies were performed with a hanheld 2-3 MHz transcranial probe       
(Aplio MX, Toshiba Medical Systems Corp., Japan) at the temporal bone 
window on both sides. The middle cerebral artery (MCA) main stem was first 
evaluated with colour Doppler and then it was insonated at the depth giving the 
optimal waveform to assure a good quality Doppler spectrum. Gosling pulsatility 
index (PI) of each MCA was calculated automatically as (systolic velocity-
diastolic velocity)/mean velocity. We only considered measurements if Doppler 
spectrum waveform envelope was of very good quality and if at least 4 
consecutive good-quality waveforms were reliable for each measurement, to 
assure accurate PI values. Therefore, not all patients had IP values for the 
study . If available, the mean value of both sides was calculated for analysis. 
Sample size calculation – falta i ho escriuré jo mateix si cal (ho tinc inclòs al 
projecte FIS).  
We calculated the sample size of each group based on the hypothesis that we 
would find frequencies of white matter lesions of 25% in the group of patients 
with retinopathy and 10% in the group without retinopathy, with and expected 
drop-out rate of 10%. This calculation yielded a sample size of 144 subjects in 
each study group that would allow an 90% power to detect differences between 
groups with a significance level of < 0.05.  
Statistical analysis 
Cal que parlem amb Emilio Ortega. Es pot fer un esborrany basant-nos en 
altres articles 
Results 
Leucoaraiosis (LA)  
MRI was performed in 289 patients (n=146 with retinopathy and n=143 without 
retinopathy). Fifty-eight patients with retinopathy (39.72%) and 44 patients without 
retinopathy (30.76%) had WMLs (p=0.063). 
Concerning the frequency of LA, no differences were observed in the percentage of 
patients with LA when patients with T2D without RD were compared to those with mild 
retinopathy (30,1% vs 30,4%). In contrast, the percentage of patients with T2D and LA 
was higher in those with a more severe grade of retinopathy compared to those with 
mild retinopathy ( 47.1% vs 30.4%, p=0.002).  
In relation to the severity of LA assessed by ARWC score, most of the patients (n=187) 
had no lesions of LA, 70 patients had mild LA, 29 patients had moderate LA and in 3 
patients LA was severe. A positive correlation was observed between the severity of 
LA and either the presence (although non-significant, p=0.052) or the grade of DR 
(p=0.0409).    
In the univariate analysis, the presence of LA was associated with age 
(p<0.001), systolic blood pressure (p=0.005), a previous diagnosis of 
hypertension (p=0.024), and the presence of carotid plaques. However, only 
age (p<0.001) and systolic blood pressure (p=0.024) were associated with LA in 
the regression analysis.  
Microbleeds  
Microbleeds were only identified in 3 patients with retinopathy (2.05%) and 5 
patients without retinopathy (3.5%) (not significantly different, p=0.45).  
Pulsatility index (PI)  
Transcranial Doppler ultrasonography results showed that differences were  
observed in the mean MCA-PI in relation to either the presence or grade of DR. 
Thus, mean MCA-PI was statistically higher in patients with DR compared to 
those without DR (0.92 (0.80-1.02 vs 1.06 (0.93-1.20) p<0.0001) and, mean 
MCA-PI was statistically higher in those with severe grades of DR compared to 
those with mild DR (1.11 (1.01-1.26) vs 0.94 (0.85-1.11), p=0.0004). No 
differences were observed when patients with mild DR were compared to those 
without DR (0.94 (0.85-1.11) vs 0.92 (0.80-1.02).  
In the univariate analysis, age (p<0.001), systolic blood pressure (p<0.0001), 
diastolic blood pressure (p=0.0008), presence of hypertension (p=0.002), 
presence of retinopathy (p=0.03), HbA1c (p=0.03) and aspirin treatment 
(p=0.0008) were associated with mean MCA-PI.  
However, in the multivariate analysis only age (p<0.0001), systolic blood 
pressure (p=0.0001), diastolic blood pressure (p=0.0001) and presence of 
retinopathy (p=0.0327) were associated with mean MCA-PI.   
Finally, a positive correlation was found between severity of LA and mean MCA-
PI. Thus those patients with more severe grades of LA (group B) had 
significantly higher values of MCA-PI than those without LA or mild LA (group A) 
(1.19 (1.098-1.32) vs 0.96 (0.86-1.11), p=0.0058).  
Conclusions 
The main finding of the present study is that patients with T2D and DR, without 
previous CV disease, show manifestations of cerebral SVD compared to those 
without DR. More specifically, those patients with more severe grades of DR 
show a more severe grade of LA and higher MCA-PI values.  
It is accepted that T2D is associated with and increased risk of stroke and 
cognitive decline. In relation to cerebral SVD, an increased prevalence of 
lacunar infarcts has been described in people with T2DM  compared to subjects 
without DM (32). The association between T2D and WM hyperintensities such 
as LA is less clear (33). In relation to cross-sectional studies performed in 
patients with T2D that have used the same methods as ours, i.e visual rating 
scales, to evaluate the presence and severity of WMLs conflicting results have 
been described. Some (12) have described a higher frequency and severity (12, 
34, 35) of WMLs compared to people without DM, specially those located in the 
deep cerebral area, while others have found no differences (11).  However, with 
the use of more sensitive brain magnetic resonance techniques, recent studies 
seem to show, more firmly than previously reported, a relationship between DM 
and both the presence and severity of LA (36). In the present study, the severity 
of LA was higher in patients with T2D and DR compared to those without DR. 
However, we found no differences in the percentage of patients with LA when 
both groups (patients with or without DR) were compared.  The low prevalence 
of LA found in our study could be influenced by the selection of our population 
study, as patients included in the present study were younger than those in 
previous studies. As in previous studies, our results show a higher frequency of 
LA in patients with a previous diagnosis of hypertension or elevated systolic 
blood pressure. As far as we know there are no data in the literature about the 
prevalence and severity of WMLs in patients with T2D in relation to the 
presence and grade of DR.     
In relation to microbleeds, an additional cerebral microvascular lesion analyzed 
in the present study, no differences were observed when T2D patients with DR 
were compared to those without DR. In general population brain microbleeds 
have been described to be associated with diabetes mellitus, hypertension (35, 
37) and retinal microvascular abnormalities (35). However, a recent study 
specifically performed in a group of 350 patients with T2D found no differences 
in microbleeds occurrence compared with a control group (4% and 6%, 
respectively) (38). This result is similar to that recently reported by Brundel M et 
al (39) that used an ultra-high field MRI for the evaluation of microbleeds. These 
results are similar to those obtained in the present study. To the best of our 
knowledge the presence of brain microbleeds and its relationship with DR has 
not previously been addressed in a population of patients with T2D.  In patients 
with T1D, the presence of proliferative DR has recently been described by 
Woerdeman J et al to be associated with a higher prevalence of brain 
microbleeds whereas not with the presence of ischemic SVD as assessed by 
WM hyperintesities on MRI without finding any difference between T1D patients 
without proliferative retinopathy and controls (4). The authors of this study 
suggest that this might be explained by its different etiology, i.e vessel wall 
leakage in cerebral microbleeds and ischaemic tissue damage in WM lesions. 
One of the possible explanations for the lack of difference in microbleeds 
prevalence between patients with or without DR in the present study might be 
due to the fact that the number of patients with T2D and proliferative DR was 
low. Another possible explanation for the differences in the prevalence of 
microbleeds between patients with T1D and T2D is that usually T2D typically 
develops in the context of a cluster of vascular and metabolic risk factors, like 
hypertension, dyslipidemia and obesity, which each could lead to brain damage 
itself. 
The pulsatility index, as derived from Transcranial Doppler ultrasound has been 
interpreted as a consequence of SVD due to changes in vascular resistance 
(40). In patients with T2D, Lippera et al described in a group of 86 T2D patients 
an increased PI in those with proliferative DR compared to those without DR or 
background DR (41). These results are consistent with those reported by Lee et 
al that described a significantly higher PI of the MCA in a group of 33 patients 
with a microvascular complication with either retinopathy, nephropathy or 
neuropathy (18).  
In general elderly population, MCA-PI has been described to correlate with 
WML severity (7, 42). In patients with recent transient ischemic attack or stroke, 
Webb et al have recently described that MCA-PI is associated with the 
presence and severity of LA as well as with both pulsatility and arterial stiffness 
in both the aorta and the MCA (43). Thus, the authors of this latest study 
suggest a causative pathophysiological relationship between LA and large 
artery stiffening. Arterial stiffness has been shown to be an independent risk 
factor for adverse cardiovascular events and all-cause mortality in the general 
population (44). In patients with T2D an increased pulse wave velocity (PWv) in 
the large arteries, a mesure used for the evaluation of arterial stiffness, has 
been described (45). In these patients arterial stiffness has also been reported 
to be independently associated with the severity of cerebral WMLs (46). On the 
other hand, in patients with T2D, DR has been independently associated with 
PWv, the severity of DR being associated with a greater peripheral vascular 
stiffness (47). The stiffening of large arteries like the aorta may promote more 
penetration of the pulsatile enery into the microvasculature of the brain with 
resulting smaller lumen and reduced vasodilatory reserve.  Several potential 
mechanisms have been proposed for the arterial wall stiffening observed in 
patients with T2D. Our group has recently described that one of these 
mechanisms may be the existence of a diabetic microangiopathic complication 
affecting the wall of the large arteries, specially in those patients with a 
microvascular complication such as retinopathy (48). To our knowledge, there 
are no data in the literature about the relationship between LA, presence and 
severity of retinopathy and MCA-PI in a group of patients with T2D.  
The present study has several limitations. A direct relationship between 
retinopathy and cerebral microangiopathy cannot be demonstrated due to the 
the cross-sectional design of the study. The lack of an age-matched control 
group without diabetes prevents the extrapolation of these results to the general 
diabetic population. The frequency of cerebral MRI findings is lower than 
expected initially to calculate the sample size. Recent studies have related 
cerebral PI to Aortic and proximal large artery stiffness (43). We cannot rule out 
this hypothesis because the study was not designed for this purpose.  
The strengths of the present study are its specific design aimed to test the 
hypothesis that the brain is a target organ to diabetic microangiopathy related to 
retinopathy. Thus, a large number of patients with retinopathy were included. All 
PI measurements were made by the same neurologyst with an standardised 
method, and only good quality individually revised Doppler spectrum waveform 
PI were used to evaluate measurements. 
In conclusion, in the present study we found that patients with T2D patients and 
DR have a more severe grade of LA and a higher MCA-PI compared with those 
without DR. These data are at the expense of those patients with more severe 
grades of DR. Moreover, a positive association has been found between LA 
severity and MCA-PI values. Future studies are needed to evaluate the 
usefulness of measuring the MCA-PI as well as the presence and severity of 
DR as possible markers of cerebral microvascular lesions in patients with T2D. 
Results of the present suggest that in T2D, DR is associated with a 
microangiopathic affection of cerebral vessels supporting the hypothesis that 
the brain is a target organ for microvascular complications of diabetes similar to 
other organs such the retina.  Thus, patients with T2D and DR could be a target 
population for screening of cerebral microangiopathy. 
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 Diabetes without 
DR(n = 159) 
Diabetes with DR(n 
= 153) 
P 
value 
Sex (male/female) 82/77 76/77 0.74 
Age (years) 59 (48–66) 61 (54–68) 0.01 
Disease duration (years) 6 (2–10) 11 (6–20) <0.01 
Insulin treatment (n) 20 (12.6%) 84 (54.9%) <0.01 
Smoking (yes/past/never) 71/54/32 78/44/30 0.51 
Antiplatelet agents (yes/no) 112/47 (29.6%) 82/71 (46.4%) <0.01 
Dyslipidemia (yes/no) 88/71 (44.7%) 79/74 (48.4%) 0.51 
Hypertension (yes/no) 83/76 (47.8%) 48/105 (68.3%) <0.01 
Systolic BP (mmHg) 134 (123–145) 143 (133–159) <0.01 
Diastolic BP (mmHg) 76 (70–83) 77.5 (68.5–85.5) 0.75 
HR (bpm) 75 (68–82) 77 (70–86) 0.08 
BMI (kg/m2) 30.3 (27.4–34.0) 31.1 (28.3–35) 0.25 
Waist circumference (cm) 103 (96–111) 107.5 (163–114) <0.01 
Hemoglobin A1c (mmol/mol) 53 (48–63) 65 (55–76) <0.01 
Hemoglobin A1c (%) 7.1 (6.5–7.9) 8.1 (7.2–9.1) <0.01 
Total cholesterol (mmol/L) 184 (163–207) 181 (162–204.5) 0.99 
HDL cholesterol (mmol/L) 47 (40–57) 50.5 (42–60.5) 0.03 
LDL cholesterol (mmol/L) 108 (90.2–130.2) 105.4 (86.5–127.8) 0.27 
Triglycerides (mmol/L) 118 (89–171) 116 (83–168) 0.62 
Serum creatinine (μmol/L) 0.79 (0.69–0.92) 0.79 (0.68–0.93) 0.80 
Urinary albumin/creatinine ratio 
(mg/g) 5.8 (3.2–11) 12.4 (6–32.7) <0.01 
Carotid plaques, n (%) 83 (52.2%) 104 (68%) <0.01 
 
 
Table 1 
Table 2. White matter lesions by MRI of the study group 
No DR Mild DR More than mild DR p-value 
WMLs presence (%) 30 30 47 0.022 
High WMLs score (%) 7.5 7.14 17.19 0.016 
MCA-PI 0.92 (0.80-1.02) 0.94 (0.85-1.11) 1.11 (1.01-1.26) <0.001 
WMLs: whitte matter lesions 
MCA-PI: pulsatility index of the middle cerebral artery 
High WMLs score: ARWC score 2-3 
